DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia
- 23 July 2026
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 117 (5) , 1301-1308
Abstract
Introduction: Thrombosis and bleeding events are major causes of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). The contribution of non‐driver mutations, in particular mutations in DNMT3A , TET2, and ASXL1 (collectively DTA) to thrombo‐hemorrhagic risk remains unclear. Methods: We conducted a retrospective analysis of 180 patients with MPN undergoing next generation sequencing to evaluate the association between DTA mutations and major bleeding and thrombotic events occurring from 3 years prior to diagnosis through follow‐up. Patients were stratified by disease subtype, and Cox proportional hazards models were used for univariate and multivariate analyses. Results: DTA mutations were present in 40% of the patients. 52 (29%) patients suffered from arterial or venous thrombotic events either following diagnosis or as early as 3 years prior to diagnosis, and 20 (11%) experienced major bleeding events during the same period. In patients with PV and ET, DNMT3A and TET2 (DT) mutations were significantly associated with venous thrombosis (HR 5.6, 95% CI 1.6–19.1) and were also associated with major bleeding in univariate analyses (HR 6.7, 95% CI 1.7–26.9). The association with venous thrombosis remained significant after multivariable adjustment, whereas the association with major bleeding was attenuated after adjustment for age and smoking status (HR 4.1, 95% CI 0.9–19.2). No such associations were observed in patients with myelofibrosis. Conclusion: Our findings highlight an association between DT mutations and thrombotic and bleeding complications in patients with PV and ET and support further evaluation of molecular markers as contributors to thrombo‐hemorrhagic risk in MPN.Keywords
This publication has 31 references indexed in Scilit:
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2024
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general populationCancer Cell, 2023
- Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score systemResearch and Practice in Thrombosis and Haemostasis, 2023
- Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspectiveThrombosis Update, 2021
- Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsCell Stem Cell, 2021
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease SubgroupsMayo Clinic Proceedings, 2019
- Risk Factors for and Management of MPN-Associated Bleeding and ThrombosisCurrent Hematologic Malignancy Reports, 2017
- Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia veraEuropean Journal of Internal Medicine, 2017
- Mutations and prognosis in primary myelofibrosisLeukemia, 2013